Thyme Care provides support and guidance specifically for cancer patients, aiming to ensure they receive high-quality care throughout their treatment journey. The company integrates with existing clinical teams to offer continuous support, utilizing technology and oncology expertise to enhance patient care. Their services include personalized guidance for patients and acting as an extension of healthcare providers' clinical teams, aligning incentives across the healthcare system. What sets Thyme Care apart from competitors is its focus on reducing the total cost of care through targeted interventions, which have been shown to lower inpatient spending and visits. The goal of Thyme Care is to deliver high-quality cancer care while also making treatment more affordable for patients and healthcare providers.

Bessemer Venture Partners

Frist Cressey Ventures

Casdin Capital

Andreessen Horowitz

AlleyCorp

Town Hall Ventures

Foresite Capital

Banc of California

CVS Health Ventures

Concord Health Partners

Echo Health Ventures

Data & Analytics

Healthcare

Thyme Care

In May, Thyme Care launched a new palliative care telehealth offering, branded as Enhanced Supportive Care.

Palliative Provider Thyme Care Secures $95M in Funding Round

Oak Street Health, EmblemHealth, Vytalize Health, and several large national health plans recognize Thyme Care's patient-centric navigation and deep provider relationships as a leading value-based model that delivers on the promise of better care at lower costsThyme Care generates savings and improves the cancer experience, fueling its national expansion across Medicare Advantage, commercial health plans, employers, provider groups, and CMS's Enhancing Oncology ModelThyme Care Oncology Partners (TCOP) doubles the number of oncologists in its network since launching in March; more than 850 oncologists represented from every major managed service organization now part of the platformNASHVILLE, Tenn., Dec. 17, 2024 /PRNewswire/ -- Thyme Care today announced new strategic partnerships across the cancer care continuum, enabling the company to achieve 4x year-over-year growth in 2025. With this momentum, Thyme Care expects to bring comprehensive cancer care support services to over 40,000 people with cancer.The cancer care system is nearing a financial and logistical breaking point, strained by systemic inefficiencies and gaps in care that burden patients, providers, and payers alike. Patients and caregivers struggle to navigate a complex and siloed healthcare ecosystem, and often experience barriers to care once they leave the physician's office. Oncologists, regardless of whether they practice in the community or a hospital setting, are not incentivized in the current fee-for-service environment to provide value-based care. These challenges inflate costs for everyone in the care continuum, bringing the entire system closer to a breaking point

Thyme Care Projects 4X Growth In 2025 As Demand For Value-Based Oncology Care Surges; New Partnerships Bring Comprehensive Cancer Care Support To Over 40,000 Patients Across The Nation

Thyme Care, a Nashville, TN-based value-based cancer care enabler, raised $95M in Series C funding.

Thyme Care Raises $95M in Series C Funding

What You Should Know:– Thyme Care, a leading value-based cancer care enabler raises $95M in funding capital led by Concord Health Partners, with participation from existing investors including CVS Health® Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Foresite Capital, and new investor SignalFire. The funding brings Thyme Care’s total funding to $178M.– Thyme Care is a value-based cancer care enabler focused on improving patient outcomes and reducing healthcare costs. The new funding will fuel Thyme Care’s expansion into new markets, deepen existing partnerships, and enhance its clinical value-based care model.Addressing the Cancer Care CrisisThe cancer care landscape is marked by escalating costs, fragmented care, and significant disparities in patient outcomes. Drug costs alone can account for up to 70% of total care expenses, with many life-saving therapies exceeding $200,000 annually. Patients often face overwhelming financial burdens, gaps in support, and a lack of care coordination.Thyme Care is addressing these challenges with a comprehensive approach that focuses on reducing costs, improving outcomes, and enhancing the patient experience.Thyme Care’s Impactful SolutionThyme Care’s value-based care model includes:24/7 specialized cancer care navigation: Guiding patients through complex treatment journeys.Guiding patients through complex treatment journeys. Advanced technology and data insights: Optimizing care delivery and identifying areas for improvement.Optimizing care delivery and identifying areas for improvement

Thyme Care Secures $95M To Expand Value-Based Cancer Care Platform

Thyme Care, a Nashville, TN-based value-based cancer care enabler, raised $95M in Series C funding

New financing paves the path to profitability as Thyme Care mainstreams value-based cancer care; capital injection will support the anticipated broad rollout...

Thyme Care Closes $95M Series C To Fuel Cancer Care Affordability

A cancer care navigation startup, Thyme Care, has raised $95 million in a Series C round from investors including Concord Health Partners, Town Hall Ventures, Andreessen Horowitz, Foresite Capital, and CVS Health Ventures. This follows a $60 million Series B round, bringing total funding to $178 million. The startup aims to help payers and providers reduce cancer care costs while improving patient health, by offering incentive payments to providers and sharing in insurers' savings.

Thyme Care raises $95M for cancer care

Skyrocketing costs of cancer care handily outpace other disease areas like heart disease and kidney care on a per-patient cost basis; expose urgent, unmet need for payers to focus on value-driving measures for cancer populationCancer's lethality is matched by its complexity, requiring personalized care plans and placing an extreme burden on both patient and provider; Echo and CVS identify Thyme Care's provider-centric approach as pivotal to proactively addressing patient needs–improving experience, outcomes, and affordabilityNew strategic investment builds on Thyme Care's leadership and will accelerate the national expansion of its comprehensive cancer care model, offering a path forward for payers and providers seeking to improve member experience and bend the cost curveNASHVILLE, Tenn., May 28, 2024 /PRNewswire/ -- Thyme Care , the leading value-based cancer care enabler, today announced investment from Echo Health Ventures , a strategic investment platform investing on behalf of multiple Blues health plans, and CVS Health Ventures , the venture arm of CVS Health. The investment will accelerate the national expansion of Thyme Care's value-based cancer care model through contracts with health plans, risk-bearing providers and with oncologists. Kurt Sheline , partner at Echo Health Ventures, and Alyssa Reisner , partner at CVS Health Ventures, will join as board observers.As the second leading cause of death in the United States, cancer's lethality is matched by its complexity and imposes an extreme economic burden for patients and payers alike. Patients often face difficulties in navigating their care due to the intricacies of a cancer diagnosis and subsequent care plan, leading to gaps in support and lack of coordination between visits. Consequently, cancer patients experience higher rates of hospitalization during treatment, contributing to increased healthcare costs across the system, with cancer costs disproportionately impacting healthcare spend."Cancer care today is challenging for everyone involved. Patients and families are forced to navigate a complex and frightening care journey, while providers struggle to offer personalized care in a rapidly evolving and often heterogeneous case mix, and health plans grapple with skyrocketing costs," said Kurt Sheline, Echo Health Ventures

Thyme Care Closes Strategic Investment From Echo Health Ventures And Cvs Health Ventures To Scale Its Value-Based Cancer Care Model

Concord Health Partners invested in Thyme Care for its ability to improve patient care and reduce costs.

Thyme Care Raises $95M To Advance Cancer Care

Thyme Care, a value-based cancer care enabler, raised $95 million in Series C financing, including $55M in equity funding from new investor Concord Health Partners and existing investors like CVS Health Ventures and a16z Bio + Health. Banc of California provided an additional $40M in debt financing. This brings Thyme Care's total funding to $178M.

Thyme Care

Tech-enabled support for cancer patients

Thyme Care

Tech-enabled support for cancer patients

About

Simplify's Take

What believers are saying

What critics are saying

What makes Thyme Care unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Thyme Care is Hiring for 0 Jobs on Simplify!